報價延遲最少15分鐘:2025/05/10 04:36 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
2.2 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.11/--
|
|
企業價值
--
|
| 資產負債 |
|
每股賬面淨值
不適用
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/05/10 04:36 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Apimeds Pharmaceuticals Us Inc is a clinical-stage company. It is engaged in a pharmaceutical business that provides the biological drug Apitox to clients in the biological drug commercial transaction area. It are a clinical stage biopharmaceutical company in the process of developing Apitox, an intradermally administered bee venom-based toxin. Company focus is on developing therapies that address inflammation and pain management symptoms associated with knee OA and, to a lesser extent, MS. Apitox is currently marketed and sold by Apimeds Inc. in South Korea as Apitoxin for the treatment of OA. |